Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions. Fair value range: low $103, high $163, with mid-point at $132.
Stock analysis
Gilead Sciences Inc.GILD Gilead Sciences Inc. fair value $132–$163
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.
§1 الملخص التنفيذي
Fairly valued with a synthesized target of $132.47 compared to a current price of $134.06.
Dominant but mature HIV franchise faces long-term growth constraints and patent expirations.
Immense free cash flow easily supports a robust dividend and ongoing strategic oncology investments.
Near-term multiple expansion requires significant commercial breakthroughs in the oncology pipeline.
Fair value
$132
Margin of safety
-1.2%
Confidence
88/100
Moat
6.5/10
Educational analysis only — not financial advice. Always do your own due diligence.
$134.06Price
FV $132.47
High $163
Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions.
Based on our latest analysis, GILD trades close to fair value. The current price is $134 versus a composite fair-value midpoint of $132 (range $103–$163), which implies roughly 1.2% downside to the midpoint.
Our composite fair-value range for GILD is $103–$163, with a midpoint of $132. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Gilead Sciences Inc.'s archetype.
Our current rating for GILD is Hold with a confidence score of 88/100. Hold. The synthesized fair value of $132.47 aligns closely with the current market price of $134.06. Upside is limited without significant pipeline success, but downside is protected by a strong fundamental yield. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Gilead Sciences Inc. are: Biktarvy LOE Collapse; Oncology Pipeline Failure; Aggressive Pricing Reform. The single biggest risk is Biktarvy LOE Collapse: Rapid market share loss following the loss of exclusivity for Biktarvy without adequate replacement from the oncology pipeline.
Our current rating for GILD is Hold, issued with a confidence score of 88/100 and a moat score of 6.5/10. The rating reflects the composite fair-value range ($103–$163) versus the current price of $134.
Gilead Sciences Inc. is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for GILD.
